Thierry Landre

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 8

Top Topics

Positron Emission Tomography

Small Cell Lung Cancer

Contrast Enhanced

Top Venues

Journal of cancer research and clinical oncology

Cancer immunology, immunotherapy : CII

This page only lists publications with an associated author ORCID identifier.

Publications

Thierry Landre, Christos Chouaïd, Nassyma Sadaoui, Djamila Bouharati, Chérifa Taleb
Clinical benefit of anti-PD-1/PD-L1 plus chemotherapy in first-line treatment for patients over the age of 65 or 75 with metastatic non-small cell lung cancer (NSCLC). Journal of chemotherapy (Florence, Italy) (2024)
Thierry Landre, Gregoire Justeau, Jean-Baptiste Assié, Kader Chouahnia, Claire Davoine, Chérifa Taleb, Christos Chouaïd, Boris Duchemann
Anti-PD-(L)1 for KRAS-mutant advanced non-small-cell lung cancers: a meta-analysis of randomized-controlled trials. Cancer immunology, immunotherapy : CII (2021)
Thierry Landre, Gaetan Des Guetz, Kader Chouahnia, Virginie Fossey-Diaz, Stéphane Culine
Immune Checkpoint Inhibitors for Patients Aged ≥ 75 Years with Advanced Cancer in First- and Second-Line Settings: A Meta-Analysis. Drugs & aging 37 (10) (2021)
Gaëtan Des Guetz, Thierry Landre, Marc A Bollet, Muriel Mathonnet, Laurent Quéro
Is There a Benefit of Oxaliplatin in Combination with Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer? An Updated Meta-Analysis. Cancers 13 (23) (2021)
Sébastien Gendarme, Helene Goussault, Jean-Baptiste Assié, Cherifa Taleb, Christos Chouaid, Thierry Landre
Impact on All-Cause and Cardiovascular Mortality Rates of Coronary Artery Calcifications Detected during Organized, Low-Dose, Computed-Tomography Screening for Lung Cancer: Systematic Literature Review and Meta-Analysis. Cancers 13 (7) (2021)
Thierry Landre, Kader Chouahnia, Gaëtan Des Guetz, Boris Duchemann, Jean-Baptiste Assié, Christos Chouaid
First-line immune-checkpoint inhibitor plus chemotherapy versus chemotherapy alone for extensive-stage small-cell lung cancer: a meta-analysis. Therapeutic advances in medical oncology 12 (2020)
Thierry Landre, Gaetan Des Guetz, Kader Chouahnia, Boris Duchemann, Jean-Baptiste Assié, Christos Chouaid
First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutation. Journal of cancer research and clinical oncology 146 (12) (2020)
Thierry Landre, Gaetan Des Guetz, Kader Chouahnia, Cherifa Taleb, Alain Vergnenègre, Christos Chouaïd
First-line PD-1/PD-L1 inhibitor plus chemotherapy vs chemotherapy alone for negative or < 1% PD-L1-expressing metastatic non-small-cell lung cancers. Journal of cancer research and clinical oncology 146 (2) (2019)